Investigational drug · Phase 2
OLX72021
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Androgenetic Alopecia (AGA).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "OLX72021"
First trial start
2025
Dec 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OLX72021", any sponsor or status.
Conditions studied
As listed on its trial records.
- Androgenetic Alopecia (AGA)
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "OLX72021" as an intervention, largest first.
- A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic AlopeciaPivotal-lookingRecruiting
Olix Pharmaceuticals, Inc.Industry
NCT07327359 · 158 participants (planned) · Start Dec 4, 2025 · Primary completion Sep 2027
Drug: OLX72021; OLX72021 and 2 more · For: Androgenetic Alopecia (AGA)
Sites: Botany, Australia; Kogarah, Australia; Newcastle, Australia · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Androgenetic Alopecia (AGA)
- VDPHL01Phase 34 trials
Veradermics, Inc. · Androgenetic Alopecia, AGA, Male Pattern Baldness
- DA-001Phase 31 trial
Applied Biology, Inc. · Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
- PDFE-2304Phase 21 trial
PDFE Pharma Innovations FZCO · Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.